Simon Greenwood, Ph.D.

Post navigation

Search

Bayer and Kumquat Biosciences initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors
Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology
Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to Advance Novel Oral Immuno-Oncology Drug Candidate
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses